Karen Wagner
InvestorGeneral Partner at Ysios Capital · Board director at KALA BIO
Zurich
Writes $1M – $7.5M checks · typically $1M
Find your path to Karen
434 people in our graph share verified history with Karen — schools, employers, funds. One of them is your warm intro.
About
Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
Contact· self-published, not guessed
Invests in
Biotech
Board director at KALA BIO
Intro paths
In turn, Karen can intro founders to KALA BIO's investors below.
KALA BIO's investors · 8
Co-founders at KALA BIO
Experience
- Ysios CapitalGeneral Partnercurrent2007 — present
- Independent ConsultantConsultant Business Development2007 — 2014
- F. Hoffmann-La Roche LtdGlobal Alliance Director2005 — 2007
- GlycArt Biotechnology AGVP Licensing2004 — 2005
- Ingenium Pharmaceuticals AGDirector Business Development2001 — 2004
- McKinsey & CompanyConsultant1998 — 2001
Skills & more
From Karen's professional profile.
Investments
Board seats
AELIX TherapeuticsCardozCytoki PharmaGalectoKala PharmaceuticalsMinoryx TherapeuticsSparingVision’s websiteSynendosVivet TherapeuticsXeltis
Investor
Cytoki PharmaGalectoKALA BIO
Sources: the firm's website · curated public sources.
Colleagues at Ysios Capital
Network1
Investors connected to Karen in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Karen Wagner?
- Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
- Where does Karen Wagner work?
- Karen Wagner is General Partner at Ysios Capital and Board director at KALA BIO.
- What does Karen Wagner invest in?
- Karen Wagner invests in Biotech.
- What check size does Karen Wagner write?
- Karen Wagner typically writes checks of $1M – $7.5M.
- What boards does Karen Wagner sit on?
- Karen Wagner holds tracked board seats at AELIX Therapeutics, Cardoz, Cytoki Pharma, Galecto, Kala Pharmaceuticals, Minoryx Therapeutics, SparingVision’s website, Synendos, Vivet Therapeutics, Xeltis.
- What companies has Karen Wagner invested in?
- Investments tracked here include Cytoki Pharma, Galecto, KALA BIO.
- Where did Karen Wagner go to school?
- Karen Wagner studied at University of Konstanz (PhD, Molecular and Cell Biology).
Same school
Also attended University of Konstanz27
+ 21 more
Shared employers
Also worked at F. Hoffmann-La Roche Ltd229
+ 223 more
Also worked at GlycArt Biotechnology AG2
Also worked at McKinsey & Company2,000
+ 1,994 more